NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$68.7m

Last Updated

2021/05/08 22:26 UTC

Data Sources

Company Financials +

Executive Summary

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. More Details


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has Cellectar Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CLRB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: CLRB's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

-13.9%

CLRB

-3.2%

US Biotechs

0.2%

US Market


1 Year Return

-21.4%

CLRB

24.4%

US Biotechs

49.9%

US Market

Return vs Industry: CLRB underperformed the US Biotechs industry which returned 24.4% over the past year.

Return vs Market: CLRB underperformed the US Market which returned 50.2% over the past year.


Shareholder returns

CLRBIndustryMarket
7 Day-13.9%-3.2%0.2%
30 Day-11.7%1.9%2.2%
90 Day-38.5%-10.6%4.2%
1 Year-21.4%-21.4%26.2%24.4%52.4%49.9%
3 Year-87.7%-87.7%27.0%20.5%63.7%53.4%
5 Year-90.1%-90.1%54.9%42.6%130.5%104.8%

Long-Term Price Volatility Vs. Market

How volatile is Cellectar Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cellectar Biosciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CLRB ($1.36) is trading below our estimate of fair value ($87.7)

Significantly Below Fair Value: CLRB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CLRB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CLRB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CLRB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CLRB is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (3.5x).


Future Growth

How is Cellectar Biosciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

28.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLRB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLRB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLRB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if CLRB's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CLRB's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CLRB's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Cellectar Biosciences performed over the past 5 years?

-18.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLRB is currently unprofitable.

Growing Profit Margin: CLRB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CLRB is unprofitable, and losses have increased over the past 5 years at a rate of 18.2% per year.

Accelerating Growth: Unable to compare CLRB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLRB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.6%).


Return on Equity

High ROE: CLRB has a negative Return on Equity (-27.55%), as it is currently unprofitable.


Financial Health

How is Cellectar Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: CLRB's short term assets ($57.9M) exceed its short term liabilities ($3.6M).

Long Term Liabilities: CLRB's short term assets ($57.9M) exceed its long term liabilities ($301.7K).


Debt to Equity History and Analysis

Debt Level: CLRB is debt free.

Reducing Debt: CLRB has no debt compared to 5 years ago when its debt to equity ratio was 19.7%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLRB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CLRB has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 8.9% each year.


Dividend

What is Cellectar Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CLRB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CLRB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CLRB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLRB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLRB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Jim Caruso (61 yo)

5.92yrs

Tenure

US$934,460

Compensation

Mr. James V. Caruso, also known as Jim, has been the Chief Executive Officer and President of Cellectar Biosciences, Inc. since June 15, 2015. Mr. Caruso served as the Chief Commercial Officer and Executiv...


CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD934.46K) is above average for companies of similar size in the US market ($USD534.46K).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CLRB's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: CLRB's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CLRB insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 437.5%.


Top Shareholders

Company Information

Cellectar Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cellectar Biosciences, Inc.
  • Ticker: CLRB
  • Exchange: NasdaqCM
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$68.686m
  • Shares outstanding: 50.50m
  • Website: https://www.cellectar.com

Number of Employees


Location

  • Cellectar Biosciences, Inc.
  • 100 Campus Drive
  • Florham Park
  • New Jersey
  • 7932
  • United States

Listings


Biography

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (P...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/08 22:26
End of Day Share Price2021/05/07 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.